Marinus Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Marinus Pharmaceuticals announced its Q3 2024 financial results, alongside a strategic review following disappointing clinical trial outcomes and a significant workforce reduction.
Marinus Pharmaceuticals reported a net loss of $74.5 million for the first half of 2024 and expressed substantial doubt about its ability to continue as a going concern.
Marinus Pharmaceuticals reported a net loss of $38.7 million for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.